65
Participants
Start Date
March 2, 2020
Primary Completion Date
March 7, 2022
Study Completion Date
February 2, 2023
Control Intervention (Conventional Autograft)
Meshed split-thickness skin graft, with standardized wound dressings (Telfa™ Clear and Xeroform™)
Investigational Intervention (RECELL + more widely meshed autograft)
More widely meshed split-thickness skin graft, Spray-on Skin™ Cells prepared using RECELL, and standardized wound dressings (Telfa™ Clear and Xeroform™)
University of Rochester Medical Center, New York
Thomas Jefferson University, Philadelphia
Temple University, Philadelphia
MedStar Washington Hospital Center, Washington D.C.
Wake Forest University Health Sciences, Winston-Salem
Duke University Hospital, Durham
Kendall Regional Medical Center, Miami
Ohio State University, Columbus
Cook County Health, Chicago
Carle Foundation Hospital, Urbana
University Medical Center, New Orleans
JPS Health Network, Fort Worth
Metis Foundation, San Antonio
Arizona Burn Center - Valleywise Health, Phoenix
University of Arizona - Banner Health, Tucson
Lundquist Institute @Harbor UCLA, Torrance
UCI Medical Center, Orange
Rhode Island Hospital, Providence
Lead Sponsor
Avita Medical
INDUSTRY